Faculty

Muhamad Alhaj Moustafa, M.D., M.S.

Clinical Studies

Expanded Access Study For The Treatment Of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel Jacksonville, FL Rochester, MN The goal of this study is to provide access to brexucabtagene autoleucel for patients diagnosed with a disease approved for treatment with brexucabtagene autoleucel, that is otherwise out of specification for commercial release.
MC230813 Phase 2 Study Of Golcadomide With Rituximab As A Bridging Therapy Prior To CAR-T For Patients With Relapsed Or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL) Albert Lea, MN Scottsdale/Phoenix, AZ Eau Claire, WI Jacksonville, FL La Crosse, WI Mankato, MN Rochester, MN
The purpose of this study is to evaluate efficacy as measured by the disease control rate (CMR, PMR, and NMR) by Lugano 2014 PET-CT based assessment after 2 cycles of therapy.

Fertility Outcomes in Lymphoma Patients Jacksonville, FL
The objectives of this study are to analyze impact of radiation on fertility, to correlate the clinical outcome of fertility after chemotherapy and or radiation, and to evaluate the different modalities and cost/benefit of fertility preservation in lymphoma patients

Lymphoma is a diversified disease with outcomes differing upon the types and subtypes of lymphoma as well as treatment modalities used. Fertility outcomes in patients treated with chemotherapy and/or radiation could vary and largely unknown.

A Phase 2 Randomized, Open Label Study To Evaluate The Efficacy And Safety Of Golcadomide In Combination With Rituximab In Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma Scottsdale/Phoenix, AZ Jacksonville, FL Rochester, MN
The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).
A Phase I/II Multicenter Study Evaluating the Safety and Efficacy of Allogeneic GDA-201 Natural Killer Cells in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma Jacksonville, FL
The purpose of this study is to evaluate GDA-201, an allogeneic cryopreserved NK cell therapy derived from donor peripheral blood, in combination with rituximab, monoclonal anti-CD20 antibody, for patients with relapsed or refractory B Cell non-Hodgkin lymphoma (NHL).